Home
overview
New biotechnology and vaccine developments are contributing to a fast growing market within anti viral therapeutics. This unique conference will explore the latest approaches to anti viral vaccines and anti viral drugs. It is desigend to be informative, stimulating and focused, examining the strategies employed by the major players within this market.

As a senior industry executive, you will be aware of the importance and potential of this field. We would therefore like to invite you to register for SMi’s conference on Advances in Anti Viral Drugs and Anti Viral Vaccine Technologies. As you will see from the brochure, key speakers include representatives from leading international pharmaceutical and biotechnology companies.

The conference offers you the opportunity to network with key industry experts. Attend to discover the potential and realities of the anti virals market, and to match your company’s resources to the needs of the consumer.

Advances in Anti Viral Drugs and Anti Viral Vaccine Technologies is organised and produced by SMi: We specialise in providing senior executives with timely, strategic and focused business information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry figures and seek their advice and opinions.

Conference programme

9:00 Chairman's Opening Remarks

Dr Jennifer Best

Dr Jennifer Best, Chairperson, Reader in Virology, European Society for Clinical Virology, King’s College London

9:10 MARKET OPPORTUNITIES WITHIN THE ANTI VIRAL VACCINE FIELD

Dr Akmal Bhatti

Dr Akmal Bhatti, Consultant/Industry Analyst, Frost and Sullivan

  • Factors driving vaccine developments
  • Vaccines: the most cost-effective of public health solutions
  • Analysis of Research and Development pipelines
  • Impact of new product launches on the vaccine market
  • Transforming vaccines into major preventative players
  • 9:40 EXPANDING PORTFOLIO OF DRUGS AND VACCINES

    Dr Michel DeWilde,

    Dr Michel DeWilde,, Vice President and Director, Research and Development, SmithKline Beecham Biologicals,, General Manager, SmithKline Beecham Immunotherapeutics

  • Discovering new vaccines
  • Developing more cost-effective and convenient combination products
  • Preventing infections which cause serious medical problems worldwide
  • Engerix B, a vaccine against Hepatitis B with unequalled experience
  • From prevention to treatment: Pharmaccines
  • 10:20 PREVENTATIVE VACCINE FOR HEPATITIS B

    Dr Michael Young

    Dr Michael Young, Chief Scientific Officer, Medeva

  • Preventative vaccination against Hepatitis B
  • Providing a third generation recombinant vaccine
  • Hepagene’sTM novelty and complexity as a biotechnology product
  • Advantages of HepageneTM
  • Benefits for the patient
  • Pharmacoeconomical aspects of HepageneTM
  • 11:00 Morning Coffee

    11:20 CHIRON: HEPATITIS C VACCINE

    Dr Sergio Abrignani

    Dr Sergio Abrignani, Head, Immunology Department, Chiron

  • Development of a preventive HCV vaccine
  • Protein vs DNA vaccine approach
  • Identification of new targets for anti-HCV therapy
  • 12:00 HOFFMANN-LA ROCHE: CASE STUDY IN THE TREATMENT OF HCV

    Dr Simon Pedder,

    Dr Simon Pedder,, Global Project Leader, Hoffmann-La Roche

  • Treatment of HCV infection
  • Interferons, their limitations
  • Phase II clinical trial results with PEGASYS™ (pegylated 40 KD interferon)
  • Safety and efficacy results with PEGASYS™
  • Combination therapy
  • Future treatments
  • 12:40 Lunch

    13:40 SCHERING-PLOUGH: TREATING HEPATITIS C

    Dr Johnson Lau

    Dr Johnson Lau, Senior Director, Antiviral Therapeutics, Schering-Plough Research

  • Treating relapse and naive hepatitis C patients
  • Mechanism of action of the Rebetol combination therapy
  • Benefits for the patient
  • Successfully receiving marketing approval for Rebetol
  • 14:20 AMARILLO BIOSCIENCES: CASE STUDY IN VIRAL INFECTIONS

    Joseph Cummins

    Joseph Cummins, President and Chief Executive Officer, Amarillo Biosciences

  • Developing low dose interferon for oral administration
  • Mechanism of action of interferon given orally
  • The use of oral interferon in the management of various human and animal diseases
  • The safety and efficacy of interferon given orally
  • Advantages of low dose interferon given orally
  • Anticipating the future of interferon given orally
  • 15:00 SCICLONE PHARMACEUTICALS: CONTRIBUTING TO THE TREATMENT OF HBV AND HCV

    Dr Alfred Rudolph

    Dr Alfred Rudolph, Chief Operating Officer, SciClone

  • Its lead product ZADAXIN® thymosin alpha1
  • Likely mechanism of action of ZADAXIN®
  • Using ZADAXIN® for the treatment of HBV and HCV
  • Enhancing the maturation and differentiation of bone marrow stem cells into T-cells
  • Suggesting new therapeutic indications for ZADAXIN®
  • 15:40 Afternoon Tea

    16:00 CHIMERIVAX™ , A NOVEL PLATFORM FOR LIVE ATTENUATED VACCINES BASED ON YELLOW FEVER 17D VIRUS

    Dr Thomas Monath

    Dr Thomas Monath, Vice President, Vaccine Research and Development,, Oravax/Peptide Therapeutics

  • Discovery and development of innovative vaccines products
  • Developing a platform technology for the construction of vaccines against a number of viral infections
  • Using their ChimeriVax™ technology
  • Developing a vaccine against Japanese encephalitis and dengue
  • Entering into joint venture partnerships
  • 16:30 PASTEUR MERIEUX CONNAUGHT: IMPROVING EXISTING HIV VACCINES

    Dr Michel Klein

    Dr Michel Klein, Corporate Vice President, Science and Technology, Pasteur Merieux Connaught

  • Developing a genetically engineered version of HIV
  • Experimenting with ‘prime-boost’ technology as an approach for developing a vaccine against AIDS
  • Combining the pseudo-virion or DNA vaccine with a canarypoxvirus vector-based vaccine
  • Anticipating the future of HIV vaccines
  • Pharmacoeconomical issues across their vaccine portfolio
  • 17:00 Chairman's Clsoing Remarks and Close of Day One

    8:30 Re-registration

    9:00 Chairman's Opening Remarks

    Dr Philip Minor

    Dr Philip Minor, Head, Division Virology, National Institue for BIological Standards and Control

    9:10 NOVEL APPROACH TO THE DEVELOPMENT OF THERAPEUTIC AGENTS FOR HIV INFECTION

    Dr Shalom Z Hirschman

    Dr Shalom Z Hirschman, President and Chief Executive Officer, Advanced Viral Research Corp

  • Reticulose: their lead anti viral drug
  • Mechanism of action of Reticulose
  • The role of the CCR5 in HIV infection
  • Decreasing the number of cellular CCR5 receptors
  • Offering a novel approach to the development of therapeutic agents for HIV infection
  • Beneficial effects of Reticulose in the treatment of HIV infected individuals
  • 9:40 DEVELOPMENT OF AN EPITOPE-BASED VACCINE

    Dr Robert W Chesnut

    Dr Robert W Chesnut, Executive Vice President, Research and Development,, Epimmune

  • The potential of epitope based vaccines
  • Using epitopes to target and activate a strong immune response
  • Creating a multi-epitope human vaccine
  • Using the EpiGene construct, a DNA vector encoding the selected epitope sequences
  • Effective delivery of multiple human HIV epitopes
  • Advantages of an EpiGene vaccine over conventional vaccines
  • 10:20 DEVELOPMENT OF A GENETICALLY DISABLED HSV-2 VACCINE

    Dr Julian Hickling

    Dr Julian Hickling, Director, Virus Immunology, Cantab Pharmaceuticals

  • Combining vaccine safety and efficacy
  • Stimulation of beneficial immune responses
  • Pre-clinical and clinical evaluation
  • Development of DISC virus technology for safe and efficient gene delivery
  • 11:00 Morning Coffee

    11:20 UTILISING CpG DNA MOTIFS TO ENHANCE AND MODULATE IMMUNE RESPONSES

    Dr Heather Davis

    Dr Heather Davis, Director of Vaccine Research and Development, CpG ImmunoPharmaceuticals

  • CpG DNA as a novel immune enhancer
  • A potent adjuvant for enhancing humoral and cellular immunity
  • A Th1 immunomodulator for therapeutic vaccines
  • A platform technology for vaccine development
  • Establishing strategic partnerships
  • 12:00 Lunch

    12:00 UTILISING NOVEL TECHNOLOGY IN THE FIELD OF DNA-BASED VACCINES

    Dr Dino Dina

    Dr Dino Dina, President and Chief Executive Officer, Dynavax Technologies

  • Establishing a broad technology platform for modulating immune system responses to antigens and allergens
  • Enhancing the ability of current and new infectious disease vaccines to produce effective immune responses
  • Developing more effective therapies for chronic infectious diseases
  • The potential of overcoming some of the current limitation of DNA-based and traditional vaccines
  • Collaborating with major corporate partners
  • 14:00 GENOMIC APPROACHES TO DISCOVERY OF NEW TARGET AND ANTIVIRAL DRUGS

    Dr Michael Dudley

    Dr Michael Dudley, Director, Discovery and Preclinical Pharmacology, Microcide Pharmaceuticals

  • The size of the antiviral therapeutics market
  • Pursuing a genetics-based programme against viral pathogens
  • Enhancing their existing technologies
  • Productive viral genomics efforts
  • Teaming up with partners
  • Anticipating the future of genomic approaches to antiviral drugs
  • 14:40 MORPHOCHEM’S EVOLUTIONARY DRUG DISCOVERY APPROACH

    Dr Alexander Dömling

    Dr Alexander Dömling, Vice President, Research and Development, Morphochem

  • The relevance of proteases as viral drug targets: assemblins
  • Multi component chemistry vs two component chemistry
  • Conventional combinatorial vs evolutionary chemistry All at once: the concept of parallel synthesis, screening, ADME and toxicology
  • All at once: the concept of parallel synthesis, screening, ADME and toxicology
  • Multiple exit points for products or ‘faster to market’
  • The benefit for pharma companies
  • 15:20 Afternoon Tea

    15:40 ADMINISTRATION OF DNA AND CONVENTIONAL VACCINES

    P Schaefer Price

    P Schaefer Price, President, PowderJect Vaccines

  • Developing a novel formulation of DNA
  • Adhering DNA to microscopic gold particles
  • Delivering the DNA-gold complex directly into the target tissue
  • Offering improved safety and efficacy over needle based delivery methods
  • Pharmcoeconomical aspects of their DNA vaccine technology
  • Benefits for the patient
  • 16:20 FOCUSING ON ORAL DELIVERY OF VACCINES

    Michael S Rosen

    Michael S Rosen, President and Chief Executive Officer, Endorex

  • Researching, developing and commercialising oral and mucosal prophylactic and therapeutic vaccines
  • Converting injectable vaccines to oral delivery
  • Demonstrating the viability of oral and mucosal delivery for certain vaccines
  • Increasing overall patient compliance and convenience
  • Partnering with major pharmaceutical and vaccine companies
  • Pharmacoeconomical aspects of an oral vaccine
  • 19:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Introducing Patents, Intellectual Property and Trademarks
    Workshop

    Introducing Patents, Intellectual Property and Trademarks

    The Hatton, at etc. venues
    15th September 1999
    London, United Kingdom

    Introducing Patents, Intellectual Property and Trademarks
    Workshop

    Introducing Patents, Intellectual Property and Trademarks

    The Hatton, at etc. venues
    15th September 1999
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.